Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders
Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...
VIVA Biotech
Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)...
Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals
Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...
Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...
AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal
AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...
Viva Biotech Establishes RMB 300M Fund for Early-Stage Pharma Projects
China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou...
VIVA Biotech Expands Global Footprint with New Boston Branch
China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...
Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program
US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...
Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...
VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...